This page shows the latest RIPK1 inhibitor news and features for those working in and with pharma, biotech and healthcare.
Sanofi’s investigational BTK inhibitor, tolebrutinib, has been shown to have a significant effect on the key central nervous system immune mediators that may drive multiple sclerosis (MS) disease progression, according ... phase 2 MS trial design for
Rigel already has ongoing pre-clinical activities with its lead CNS penetrant RIPK1 inhibitor candidates. ... The ethos behind RIPK1 inhibitor development is to offer a new kind of approach towards treating a range of autoimmune, inflammatory and
More from news
Approximately 1 fully matching, plus 1 partially matching documents found.
No results were found
Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...